Johnson & Johnson has partnered with Cue to develop a portable, inexpensive and internet-enabled HIV viral load test that would enable physicians in poor countries to more easily determine if a particular drug regimen is effective or not.
As the Zika epidemic rages on, health experts are calling for the development of blood tests that can quickly and accurately pinpoint the virus and shed light on an associated condition in infants.
Dx Digest: Illumina inks four genetic research deals; Trovagene makes moves in liquid biopsy with additional coverage for tests
In this week's Dx Digest, Illumina inked four biobanking deals to spur genetic research, liquid biopsy player Trovagene nabbed a coverage agreement for its cancer diagnostics, and diagnostics heavyweight Qiagen joined forces with genomics firm CosmosID to launch a metagenomics and microbiome analysis tool.
Boston-based BioDirection has raised a $4 million Series B round to back its point-of-care traumatic brain injury test Tbit. The financing is expected to enable the startup to finalize development and to start commercial planning for the test.
Theranos, which has been facing growing pushback for its proprietary testing technology, has hired hot-shot litigator David Boies to see it through the eye of the storm. But Boies will not only be proffering legal advice; he is also acting as a Theranos director, which could present a conflict further down the road as the company struggles for redemption.
With Zika cases on the rise and the World Health Organization recently declaring a public health emergency, government officials and the industry are looking for medications and vaccines to stop the virus' spread. But more attention should be paid to diagnostics as a tool to curb Zika outbreaks, one industry advocate said.
Problems keep piling up for Theranos, and the latest chapter in the company's ongoing testing saga isn't looking any better. Pennsylvania health insurer Capital BlueCross is scaling back its relationship with Theranos, days after the Centers for Medicare & Medicaid Services came down on the company for serious issues at its California lab.
Cue the sad violin: It's more bad news for Theranos. A day after the Centers for Medicare & Medicaid Services came down on the company for dangerous practices at its Newark, CA, facility, Walgreens Boots Alliance, one of Theranos' main partners, is severing some of its ties to the controversial blood-testing lab.
The Centers for Medicare & Medicaid Services has published a letter to Theranos director Dr. Sunil Dhawan saying that the diagnostics company's Newark, CA, laboratory is not in compliance with the agency's CLIA regulations, and "based on the Condition-level requirement at C.F.R. § 493.125, Hematology, it was determined that the deficient practices of the laboratory pose immediate jeopardy to patient health and safety."
Dx Digest: Roche and Lilly team up for Alzheimer's testing; Quanterix sets sights on Asia, weighs IPO for 2016
In this week's Dx Digest, Roche Diagnostics teamed up with pharma heavyweight Eli Lilly to create a new test for Alzheimer's. Quanterix is setting its sights on Asia for growth and is mulling an IPO to spur development of its diagnostic device, Simoa. And OncoCyte struck a deal with The Wistar Institute to market a liquid biopsy test for lung cancer.